

December 9, 2019



# OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

*OncoSec President and CEO Daniel J. O'Connor Explains How Transaction Benefits Shareholders*

*Encourages Shareholders to Vote "FOR" the CGP/Sirtex Transaction on the **WHITE** Proxy Card Today*

SAN DIEGO & PENNINGTON, N.J.--(BUSINESS WIRE)-- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Executive Officer, Daniel J. O'Connor, discussing why shareholders should vote in favor of the proposed strategic transaction with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") (the "Transaction").

**OncoSec encourages all of its shareholders to watch the video at**  
**<https://advancingoncosec.com/>**

In the video, Mr. O'Connor emphasizes that the Transaction gives OncoSec the opportunity to propel itself forward and improve its stock performance, while confronting the current challenges facing the biotechnology market.

"I don't like where the stock price is today and I haven't for a long time," said Mr. O'Connor. "We as a company are doing everything we can to change that – and the proposed CGP/Sirtex strategic transaction gives us the opportunity to do so."

Specifically, Mr. O'Connor notes three critical benefits of the Transaction:

1. Provides OncoSec the capital needed to complete its ongoing clinical studies;
2. Eliminates the need to raise capital for the foreseeable future; and
3. Provides certainty for OncoSec's shareholders.

Additional information about the Transaction and how to vote can be found at  
<https://advancingoncosec.com/>.

**Vote "FOR" the CGP/Sirtex Transaction on the **WHITE** Proxy Card Today**

**If you have any questions on how to vote, please contact the Company's proxy solicitor at the contact listed below:**

MORROW SODALI

509 Madison Avenue, Suite 1608

New York, NY 10022

Stockholders Call Toll Free: **(800) 662-5200**

E-mail: [ONCS@morrowsodali.com](mailto:ONCS@morrowsodali.com)

## About CGP

CGP is a public company listed on the Hong Kong stock exchange with a market capitalization of approximately \$1.8 billion USD. CGP develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organisations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialisation in China. Such experience dealing with the relevant Chinese regulatory bodies makes CGP an ideal strategic partner for OncoSec as it looks to gain regulatory approval to introduce TAVO™ to the Chinese market. For more information, visit [www.chinagrandpharm.com](http://www.chinagrandpharm.com).

## About Sirtex

Sirtex is a global healthcare business company with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centers in over 40 countries. Sirtex's global focus on drug development makes it a natural partner for the Company as it looks to develop and introduce TAVO™ into markets around the world. For more information, visit [www.sirtex.com](http://www.sirtex.com).

## About OncoSec Medical Incorporated

OncoSec Medical Incorporated (the “Company,” “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit [www.oncosec.com](http://www.oncosec.com).

TAVO™ trademark of OncoSec Medical Incorporated.

SIR-Spheres® is a registered trademark of Sirtex Medical US Holdings, Inc.

### **Important Additional Information and Where to Find It**

This communication is being made in respect of the proposed transaction involving the Company, Grand Decade Developments Limited, a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited, and Sirtex Medical US Holdings, Inc. The Company has scheduled a special meeting of stockholders (the "Special Meeting") in connection with the proposed transaction. The Company has filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission (the "SEC") in connection with the solicitation of proxies for the Special Meeting. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE COMPANY'S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a free copy of the proxy statement and accompanying WHITE proxy card, any amendments or supplements to the proxy statement and other documents that the Company files with the SEC from the SEC's website at [www.sec.gov](http://www.sec.gov) or from the Investor Relations section of the Company's website ([www.oncosec.com](http://www.oncosec.com)) after such materials are electronically filed with, or furnished to, the SEC.

### **Risk Factors and Forward Looking Statements**

This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumption. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the SEC. In particular, you should be aware that the strategic transaction with CGP and Sirtex may not close or may close on materially different terms, that Alpha may succeed in obtaining the relief it seeks in its litigation against the Company, in whole or in part, even though the Company believes that Alpha's litigation is entirely without merit and that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors

and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's website [www.sec.gov](http://www.sec.gov)), as well as other factors described from time to time in the Company's filings with the SEC.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20191209005434/en/>

**Investor Contact:**

Morrow Sodali  
Chris Rice / Mike Verrechia  
800-662-5200  
[ONCS@morrowsodali.com](mailto:ONCS@morrowsodali.com)

**Media Contacts**

Gem Hopkins  
Head of Corporate Communications  
858-210-7334  
[ghopkins@oncosec.com](mailto:ghopkins@oncosec.com)

or

Sloane & Company  
Dan Zacchei / Joe Germani, 212-486-9500  
[dzacchei@sloanepr.com](mailto:dzacchei@sloanepr.com) / [jgermani@sloanepr.com](mailto:jgermani@sloanepr.com)

Source: OncoSec Medical Incorporated